INTRODUCTION

Protracted recovery of naive CD4
1 T cells in recipients of allogeneic hematopoietic stem cell transplantation may result in a prolonged susceptibility to life-threatening opportunistic infections [1] [2] [3] . Reconstitution of naive CD4
1 T cells depends on the differentiation of stem cell-derived lymphoid progenitor cells into mature, naive CD4 1 T cells in the thymus (ie, thymopoiesis). Recovery of thymopoiesis has been shown to be pivotal for the generation of a new diverse T cell receptor repertoire and long-term immunity [4] [5] [6] . High-dose chemo-and radiotherapy, aging and graft-versus-host disease (GVHD) may adversely affect both the thymic stromal compartment and developing thymocytes, resulting in impaired CD4
1 T cell recovery following allogeneic hematopoietic stem cell transplantation (HSCT) [7] [8] [9] . Strategies to protect the thymic stroma or to stimulate thymocyte development may improve the recovery of naive T cells and restore the repertoire to combat a variety of infectious microorganisms [10] [11] [12] . Keratinocyte growth factor (KGF) is a growth factor that protects thymic stroma, whereas stem cell factor (SCF) stimulates outgrowth of T cell progenitors.
KGF was initially discovered as a stimulator of epithelial cell growth and is produced by cells of mesenchymal origin. Its receptor is expressed by epithelial cells including thymic epithelial cells [13, 14] . Exogenous KGF experimentally enhances thymopoiesis in normal mice, reverses age-associated thymic involution, and protects thymic epithelial cells against damage caused by irradiation, chemotherapy, and GVHD [15] [16] [17] [18] . Thymic regeneration and T-cell reconstitution were enhanced in mice and nonhuman primates treated with KGF before allogeneic or autologous HSCT [14, 17, 19] .
SCF is a cytokine produced by stromal cells including thymic stroma and c-kit; the SCF receptor is expressed by the earliest thymocytes [20] [21] [22] [23] . SCF is important for proliferation and differentiation of early thymic T cell progenitors in vitro and in vivo. c-kit 2/2 or SCF 2/2 mice show a block in thymocyte differentiation [24, 25] , and SCF 2/2 thymi poorly support early thymocyte expansion [26] . In addition, differentiation of early thymic progenitors into the T cell lineage is dependent on c-kit signaling and Notch-and IL-7-induced proliferation require c-kit signaling in vitro [27] . Administration of SCF in mice accelerated leukocyte recovery following radiation-induced myeloablation [28] but not following 5-fluorouracil (5-FU) treatment [29] or myeloablative HSCT [30] . Recently, we showed that SCF administration improved thymopoiesis in a humanized mice model [31] . In the present study, we evaluated the effect of KGF alone or combined with SCF on T cell reconstitution and thymopoiesis following myeloablative autologous HSCT into rhesus macaques.
MATERIALS AND METHODS
Animals
Purpose-bred male rhesus monkeys (Macaca mulatta), weighing 2.9-3.8 kg and age 2.5-3.7 years, were used. Monkeys were housed in groups of 4 to 6 in stainless steel cages in rooms equipped with a reverse filtered air barrier, normal daylight rhythm, and conditioned to 20 C with a relative humidity of 70%. Animals were fed ad libitum with commercial primate chow and fresh fruits, and received acidified drinking water. All animals were free of intestinal parasites, and seronegative for herpes B, simian T-lymphotropic viruses, and simian immunodeficiency virus. Housing, experiments, and all other conditions were approved by an ethical committee in conformity with legal regulations in the Netherlands. Studies with rhesus monkeys were done sequentially using highly codified methods, including radiation and placebo controls at regular intervals. For the present study, assignment to the study groups was random.
Collection of CD34
1 Hematopoietic Progenitor Cells Bone marrow (BM) was aspirated and low-density cells isolated as previously described and red blood cells reinfused immediately after cell separation [32, 33] . CD34 1 cells were isolated by immunomagnetic separation using an IgG2a antibody against CD34 (mAb 561 kindly provided by T. Egeland, University of Oslo, Oslo, Norway), which was noncovalently linked to rat-antimouse IgG2a beads (Dynal, Oslo, Norway) [34] . CD34
1 cells devoid of the anti-CD34 antibody were recovered using a polyclonal antibody against the Fab part of the anti-CD34 antibody (Detachabead, Dynal). CD34-selected cells (10 6 /kg) were reinfused into the monkeys within 24 hours after radiation.
Total Body Irradiation (TBI) and Supportive Care
Rhesus monkeys were irradiated with a single dose of 9 Gy TBI delivered by a 6-MV linear accelerator (Siemens [Siemens Healthcare, Erlangen, GE]) as described [33] . Two weeks before TBI, the monkeys were placed in a laminar flow cabinet, the gastrointestinal tract was selectively decontaminated, and iron ws supplemented as previously described [32, 33] . Supportive care after irradiation by infection prevention, transfusions, and maintenance of a hydration state were done as previously described [32, 33] . Platelet transfusions had a mean volume of 12.8 6 3.4 mL and contained 7.0 6 3.0 Â 10 9 /L platelets. Whole-blood transfusions consisted of 38.1 6 10.8 mL, containing 0.17 6 0.05 Â 10 12 /L erythrocytes and 10.0 6 3.1 Â 10 9 /L platelets.
Cytokine Administration
Recombinant human KGF (palifermin, Kepivance Ò ) and recombinant human stem cell factor (SCF) were kindly provided by Amgen (Thousand Oaks, CA). One group of animals (n 5 2) received KGF at a dose of 200 mg/kg body weight by intravenous bolus at days 23, 22, 21, 0, 11, and 12. A second group of animals (n 5 2) received both KGF and SCF. SCF was administered at a dose of 200 mg/kg body weight by subcutaneous injection daily from day 5 until day 45 posttransplantation and KGF as outlined above [35, 36] . A third group of animals (n 5 2) was used as control group and received phosphate-buffered saline (PBS) injections (Figure 1 ).
Collection of Peripheral Blood and Tissue Samples
Complete blood cell counts were measured daily using the ABC-vet animal blood counter (Scil, ABX diagnostics, Montpellier, France). Peripheral blood and BM samples for flow cytometry and molecular analysis were drawn once weekly. Animals were euthanized between day 190 and 212 following transplantation, and lymphoid tissues were collected and either processed into a single-cell suspension or fixed in 10% formalin and paraffin-embedded for light microscopic analysis. Thymic architecture was graded using a previously described grading system [19] .
Flow Cytometric Analysis
At weekly intervals, absolute numbers of peripheral blood leukocyte subsets were determined by single platform flow cytometry as described previously for murine experiments [37] . mAbs against rhesus macaque epitopes used for flow cytometric analysis were anti-CD45 (D058-1283), anti-CD3 (SP34-2), anti-CD4 (L200), anti-CD8 (SK1/2ST8.5H7), anti- ).
Real-Time Quantitative PCR (RQ-PCR)
Signal-Joint T Cell receptor excision circles (sjTREC) DNA was purified from peripheral blood at serial time points after transplantation and from organ/ thymic cell suspensions at necroscopy using the QIAamp DNA minikit (QIAGEN, Chatsworth, CA) according to the manufacturer's instructions. sjTRECs were detected using a RQ-PCR as previously described [39] for murine sjTREC with 5 0 -nuclease-based RQ-PCR assay using the ABI Prism 7700 sequence detector (Applied Biosystems, Bedford, MA) and modified for rhesus monkeys. Primers and probes for rhesus monkey sjTREC were: forward primer: 5 0 -ACATCCC TTTCAACCATGCT-3 0 , reverse primer: 5 0 -GCCA GCTGCAGGGTTTAGG-3 0 , and probe: FAM-5 0 -ACGCCTCTGGTTTTTGTAAAGGTGCTCAC T-3 0 -TAMRA [40] ; internal control GAPDH: forward primer: 5 0 -TGACCTGCCGTCTGGAAAA-3 0 , reverse primer: 5 0 -CTCCGACGCCTGCTTCA-3 0 , and probe: FAM-5 0 -CCTGCCAAGTACGATGA-CATCAAGAAGGTG-3 0 -TAMRA. In peripheral blood, sjTREC frequency (sjTREC/10 5 CD31 T cells) and sjTREC content (sjTREC/mL blood) were determined at weekly intervals. At autopsy, thymic, splenic, and LN sjTREC frequencies were determined.
Rhesus Macaque Cytomegalovirus (rhCMV)
DNA was isolated from plasma samples at serial time points after transplantation and analyzed using a modified version of a previously described rhCMVspecific RQ-PCR [41] . Briefly, plasma viral DNA was isolated using the total nucleic acid kit on a Magna Pure LC robot (Roche Applied Science, Indianapolis, IN). Primers and probes for the detection of rhCMV were based on a 108-bp amplicon of the exon-1 region of the immediate-early gene of rhCMV (ATCC-VR-677; GenBank Accession No. M93360 [42] , forward primer 5 0 -GTTTAGGGAACCGCCATTCTG-3 0 , reverse primer 5 0 -GTATCCGCGTTCCAATGCA-3 0 , and probe FAM-5 0 -TCCAGCCTCCATAGCCGGG AAGG-3 0 -TAMRA). Quantification was based on Figure 1 . Experimental design. Animals were started on selective decontamination of the gut (SDD) 12 days before HSCT. On day 26, autologous BMC were harvested by bone marrow puncture. After TBI, animals underwent HSCT. Three treatment groups were compared: 1 control group receiving PBS (n 5 2), 1 group receiving KGF from day 23 until day 2, and 1 group receiving KGF combined with SCF (day 5 until day 45). Complete blood counts (CBC) were monitored daily until day 45 and weekly thereafter. Blood flowcytometry, sjTREC analysis, and rhCMV viral load was performed weekly. BM was harvested weekly from week 0 until week 6 and week 4 weekly thereafter. TT vaccination was administered at day 50 and day 78, TT response was monitored weekly from day 45 until day 99. Animals were euthanized and underwent necropsy to collect all lymphoid tissue at the end of the study.
Biol Blood Marrow Transplant 18: [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] 2012 an external standard curve using rhCMV, which was treated exactly like the material of interest. The rhCMV DNA concentration in the samples was calculated using the data from the standard curve, as described previously [43] .
Analysis of Humoral Response against Tetanus Toxoid
Animals were vaccinated with 40 IE tetanus toxoid (Netherlands Vaccine Institute) at days 50 and 78 after HSCT. Antibodies against tetanus toxoid were measured before the start of the experiment and at time points before and after vaccination using a sensitive enzymelinked immunosorbent assay with a detection limit of 10 pg/mL and quantified as described before [44] .
Computed Tomography (CT) Scan
CT evaluation of liver, thymus, and spleen volume before (day 14) and following treatment (day 45 and before termination of experiment) were determined as described by Storek et al. [45] . On analysis, the area of the thymus was determined on each slice (mm 2 ) using intravenous contrast images, and the area was multiplied by the slice thickness to get the volume at that slice level (mm 3 ). Thymic volume was calculated as the sum of the volumes at each slice level. Splenic and liver volumes were determined analogously. In addition, thymic density was measured as outlined previously [46] .
RESULTS
Animals received 10
6 CD34 1 -selected mononuclear bone marrow cells (BMC)/kg body weight following a single dose of 9 TBI, and were treated and monitored as outlined in the Materials and Methods section (Figure 1 ). Two animals receiving PBS and 2 animals receiving KGF alone completed the experiment without any significant adverse events. The 2 animals receiving KGF and SCF did not complete the experiment. One animal (UAN 6027) died at day 45 following transplantation, which was preceded by diarrhea, bad drinking, severe weight loss (Supplemental Figure S1 ), and development of maculopapular skin lesions and petechiae. Autopsy revealed a small bowel hemorrhage and diffuse erythematous maculopapular skin lesions, possibly caused by a generalized simian varicella virus infection. The second animal (UAN 5277) was sacrificed at day 150 following transplantation because of respiratory failure unresponsive to steroids. Of note, animal UAN 5277 was treated with dexamethasone from day 106 until its death at day 150 posttransplantation. rhCMV was reactivated during this entire treatment period, coinciding with CD4
1 T-cell and B-cell lymphopenia (data not shown). Autopsy showed severe radiation-induced interstitial pulmonary fibrosis. Hematologic recovery in KGF/SCF-treated animals appeared comparable to the KGF-treated animals as outlined in detail in the next paragraph.
Animals were monitored for loss and subsequent recovery of body weight. Animals receiving KGF alone showed less loss of body weight and recovered more rapidly compared with PBS-treated control animals. The 2 controls both lost a maximum of 10% body weight compared with 4% and 7% in the 2 KGFanimals and 6% and more than 10% in the animals treated with KGF and SCF. The body weight of both PBS-treated animals recovered to pretransplantation values as of day 71, compared with days 19 and 46 for the 2 KGF-treated animals and day 42 for the 1 KGF/SCF-treated animal (UAN 5277) (Supplemental Figure S1 ).
Hematologic Recovery
Hematologic recovery appeared slow in PBStreated animals. In contrast, KGF-treated animals showed a more rapid recovery of platelets, erythrocytes, and leukocytes (Table 1) . Platelets (.50 Â 10 9 /L) were recovered by day 33 posttransplantation in both PBStreated animals, by day 24 and day 28 in KGF-animals, and by day 34 and day 24 in animals receiving the combination of KGF and SCF. In PBS-treated animals, transfusion continued until days 32 and 35, in KGF-treated animals until days 23 and 27, and in 
Lymphocyte Recovery
Lymphocyte recovery appeared more rapid in animals treated with either KGF or KGF and SCF compared with PBS. Absolute lymphocyte count (.0.5 Â 10 9 /L blood) count recovered by days 31 and 32 in the 2 PBS-treated animals, by days 21 and 15 for the 2 KGF-treated animals, and by days 25 and 21 for the 2 KGF/SCF-treated animals ( Table 1) . We next analyzed the recovery of the various lymphocyte subsets. Recipients of KGF tended toward a more rapid and enhanced recovery of B cells (Figure 2A ), whereas NK cell recovery appeared comparable to PBS-treated animals ( Figure 2B) . B cell numbers recovered to median pretransplantation values by days 71 and 64 in PBS-treated animals, by days 43 and 50 in KGFtreated animals, and by day 43 in 1 KGF/SCFtreated animal. In addition, KGF-treated animals showed significantly higher B cell numbers in peripheral blood (Wilcoxon rank test P \ .05) and in spleen and LN at the end of the experiment (Table 3 ).
Naive T Cell Recovery
Next we investigate the recovery of T cells and their various subsets. The effect of KGF combined with SCF on T cell recovery could not be assessed, because the animals died while being lymphopenic. Figure 2 and Table 2. Total  CD3 1 , CD4 1 , and CD8 1 T cell recovery were comparable between PBS-and KGF-treated animals. The recovery of naive CD4 1 ( Figure 2C ) and CD8
1
T cells in peripheral blood was not enhanced in peripheral blood. In contrast, the absolute number of CD4 1 Foxp3 1 Treg appeared higher as of day 140 posttransplantation onward in KGF-treated animals compared with PBS-treated animals ( Figure 2D ).
T cell subsets were also evaluated in the spleen and LN at the end of the experiment (Table 3 ). The frequencies of CD4 1 and CD8 1 T cells in LN and spleen were higher in KGF-treated animals compared with 1 T cells measured 7% and 10% in PBS animals and 30% and 17% in KGF-treated animals. In addition, the frequency of Treg was higher in the spleen and LN of KGF-treated animals.
Thymopoiesis
Enhanced recovery of naive T cells was observed in the LN and spleens of KGF-treated animals. To assess whether improved recovery could be because of improved thymopoiesis, we measured sjTREC 1 T cells/mL blood before and weekly after transplantation in peripheral blood; measured thymic size and density using CT scan in time; evaluated the presence of sjTREC 1 cells in thymus, spleen, and LN; and evaluated the thymus microscopically at the end of the experiment.
Pretransplantation median sjTREC1 T cell content measured 2286 sjTREC1 T cells/mL blood (range: 519-13.597). Following autologous stem cell transplantation, sjTREC1 T cells were undetectable up to 11 weeks after transplantation, but subsequently reappeared in all animals, as depicted in Figure 3 . sjTREC 1 T cell recovery was improved in KGF-treated animals as of day 106 posttransplantation as compared with PBStreated animals. sjTREC1 T cell content never recovered to normal pretransplantation values (.25th percentile) in PBS-treated animals, whereas sjTREC 1 cell numbers had recovered within normal ranges around days 85 and 134 in KGF-treated animals.
Serial CT scanning of the thymus (weeks 22, 6, 28) showed no significant differences in thymic size or density between KGF-and PBS-treated animals (data not shown). Thymi were microscopically evaluated for the degree of atrophy. Thymic atrophy was comparable for PBS-and KGF-treated animals. The thymus of PBS-treated animals showed grade 1 and 3 thymic atrophy, and KGF-treated animals showed grade 1 and grade 2. Thymocyte subset distribution, as determined by flowcytometry, was not different in PBS-or KGFtreated animals (data not shown). Thymic sjTREC 
Functional T Cell Immunity
To evaluate whether improved T-cell reconstitution would result in superior functional immunity, endogenous rhCMV reactivation was monitored weekly by RQ-PCR (Figure 4) . The 2 control animals experienced 3 and 2 self-limiting episodes of rhCMV reactivation. The 2 KGF-treated animals experienced 4 and 2 episodes, respectively. The maximum viral load was 590 gEq/mL plasma in control animals and 1320 gEq/mL plasma in KGF-treated animals. Of note, animal UAN 5277 (KGF and SCF) was treated with dexamethasone from day 106 until its death at day 150 posttransplantation. rhCMV was reactivated during the entire treatment period, coinciding with CD4 1 T-cell and B-cell lymphopenia (data not shown).
Animals were also challenged with tetanus toxoid (TT) at days 50 and 78. Anti-TT antibody levels were measured before and after immunization to determine the T-cell-dependent antibody response. As depicted in Figure 5, antibodies were absent before immunization. All animals developed an antibody response from 3 weeks after primary vaccination. Antibody responses were further increased in all animals following a boost vaccination at day 78. The highest antibody levels measured 8.3 Â 10 4 and 4.6 Â 10 4 ng/mL in PBS-treated animals versus 1.6 Â 10 4 and 1.0 Â 10 5 ng/mL in KGF-treated animals. Peak antibody levels in 2 KGF-treated animals were observed at days 85 and 92. In contrast, antibody levels were still increasing in both PBS-treated animals at day 99.
DISCUSSION
Recapitulation of thymopoiesis is generally considered pivotal for full restoration of anti-infectious immunity in the later (.3-6 months) posttransplantation time period [3, 10, 11] . Increasing age, GVHD, and high-dose chemo-and/or radiotherapy all adversely affect thymopoiesis and are associated with a protracted immune reconstitution in stem cell transplant recipients. Strategies to accelerate recovery of thymopoiesis are expected to improve anti-infectious immunity and outcome. One such strategy is the exogenous supply of growth factors that play an important role in thymopoiesis. In the present study, rhesus macaque recipients of autologous CD34
1 -selected stem cell grafts experienced a particularly slow recovery of newly developed, naive T cells. Improved thymopoiesis was noted in recipients of KGF. However, improved thymopoiesis was only modestly associated with enhanced T cell recovery, which did not translate into improved functional immunity. BM CD34 1 cells, B cells, and hematologic recovery also tended to be more rapid in KGF-treated animals. Although we also set out to evaluate the combination of KGF and SCF, severe adverse events and early death precluded a meaningful evaluation of KGF and SCF on thymopoiesis.
The 2 animals treated with the combination KGF and SCF suffered ongoing rhCMV infection and respiratory failure, and a fatal varicella virus infection, respectively. In addition, these infectious complications were preceded by mast cell-related adverse effects, including skin reactions and shivering. In previous studies of SCF in primates, most side effects were mast cell-related [47] [48] [49] [50] [51] . Of note, experimental animals in our studies received 200 mg/kg SCF daily from day 5 until day 45 posttransplantation. The inflammatory response of the conditioning regimen combined with the early start of relatively high-dose SCF administration may have provoked the toxicity observed, as a similar dosage scheme had not been associated with severe adverse effects when started late after transplantation [36] . Further preclinical studies are needed in order to develop a better tolerable therapeutic protocol that may possibly be evaluated clinically. Given the direct stimulatory capacity of SCF alone on human thymopoiesis, as recently demonstrated in a humanized mouse model [31] , further study of the combination of KGF and low-dose SCF may still be warranted. Alternatively, continuous rather than bolus dosing may be an appropriate method to limit SCF toxicity without losing beneficial effects on thymopoiesis [52] .
Our data may suggest that KGF treatment resulted in improved engraftment following myeloablative stem cell transplantation (Table 1 ). An accelerated recovery of platelets, erythrocytes, and leukocytes was noted in KGF-treated animals. These data may differ from recent studies, which did not show an effect of KGF on hematologic recovery following stem cell transplantation in both humans and nonhuman primates [19, 53, 54] . Neutrophil recovery .0.5 Â 10 9 /L occurred between days 20 to 25 in the present study, whereas Seggewiss et al. [19] reported neutrophil recovery between days 8 to 13 in a similar model. Possible explanations for the delayed hematologic recovery observed in the present study may be a relatively low numbers of CD34 1 BMC infused and, more likely, the use of granulocyte colony stimulating factor until neutrophil recovery in the Seggewiss study. An accelerated overall hematologic recovery as observed in the present study in animals receiving KGF versus controls could possibly be explained by the infusion of different subsets of CD34 1 progenitor cells, whereby KGFrecipients could have received a higher number of more primitive CD34
1 Dr dull hematopoietic progenitor cells, possibly resulting in better overall recovery. However, subsets of CD34 1 cells were not quantified in the present study, and the number of experimental animals per treatment group was rather limited. Apart from the suggestion of better hematologic recovery, thymopoiesis appeared improved in recipients of KGF, as demonstrated by the steady increase in time in sjTREC1 T cells in peripheral blood. Previous murine studies have shown that KGF improves thymopoiesis following congenic and allogeneic HSCT [ 14, 17, [55] [56] [57] . In addition, KGF was recently evaluated in a model of autologous HSCT in rhesus macaques and appeared to improve recovery of sjTREC1 T cell frequency and preserved thymic architecture [19] . Our data are in line with those reported by Seggewiss et al. [19] . We monitored sjTREC1 T cell content (sjTREC1 T cells/mL blood) on a weekly basis. As the sjTREC1 T cell frequency may be affected by proliferation of mature Tcells, evaluation of thymopoiesis by sjTREC1 T cell content may be a preferred estimate of posttransplantation thymopoiesis [58] .
Improved sjTREC 1 cell recovery in thymi and lymphoid organs of KGF animals further elaborated the data obtained in peripheral blood. However, improved thymopoiesis resulted only in a minor improvement of naive T cell recovery, which was predominantly observed in the LN and spleen. Functional T celldependent immunity, as measured by protection against endogenous rhCMV reactivation and the anti-TT antibody response, appeared not to be improved by KGF. These results appear to contrast to the improvement of antibody response against HIV envelope gp140 observed in KGF-treated animals in the study by Seggewiss et al. [19] . However, the improvement they observed was modest, was only statistically significant when combining KGF-treated groups of animals, and functionality was evaluated at a late time point following transplantation. In addition, differences with respect to transplantation protocol and vaccination scheme may additionally explain the different observation in these 2 studies. Our results compare well to a number of other preclinical studies, showing no improvement or only minor improvement of functional immune competence by KGF [14, 17, [55] [56] [57] . Collectively, these studies and our results suggest that KGF alone may be insufficient to restore T cell-dependent immune competence after myeloablative stem cell transplantation in humans. The limited clinical experience so far seems in line with that conclusion [53, 59] .
Alternative possibilities to obtain a more rapid and pronounced effect on thymopoiesis may include the combination of cytokines such as KGF and early acting cytokines such as Flt3L, IL-7, and SCF. In the present study, we planned to evaluate the effect of the combination of KGF with SCF on thymopoiesis. However, severe adverse events before T cell recovery precluded any conclusion with respect to a possible thymopoietic effect. However, given the favorable direct effects exerted by SCF on human thymopoiesis in our humanized mice model, further experimental studies are warranted. Financial disclosure: J.J. Cornelissen is a consultant for Novartis-Oncology The Netherlands.
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